Abstract 894P
Background
Technically unresectable oral cavity squamous cell cancers (OCSCC) are non-amenable to upfront surgery. Neo-adjuvant chemotherapy (NACT) can downstage the tumor and facilitate surgical resection. Pathological complete response (PCR) post NACT is a surrogate endpoint of overall survival in rectal and breast cancers. However, it’s importance in patients with borderline resectable OCC is unknown.
Methods
This was an institutional review board approved retrospective analysis of a prospectively collected dataset of borderline resectable OCSCC patients who received NACT. Adult patients with an Eastern Co-operative Gncology Group (ECOG) performance status (PS) 0-2 who were deemed as technically unresectable in a multi-disciplinary clinic (MDC) were included. These patients received 2-3 cycles of NACT (3-weekly) and underwent a response assessment. Depending on response and general condition, they were re-assessed in MDC and further therapy was decided. Patients with good general condition who became resectable underwent surgery followed by appropriate adjuvant therapy. Overall survival (OS) was calculated from date of diagnosis to date of death. Kaplan-Meier method was used for estimation of OS. Impact of pathological response on OS was assessed using the log-rank method.
Results
929 patients underwent surgery followed by adjuvant CTRT in 26.7% patients or adjuvant RT in 1.3% patients. 76 (8.2%) patients attained pathological complete response. 871 (93.8%) achieved negative margins. Three hundred forty (39.3%) patients had pT4 disease. Lympho-vascular invasion was seen in 53 (5.7%) while peri-neural invasion was seen in 186 (20.0%) patients, and 338 (36.4%) had extra-nodal extension. The median OS of entire cohort was 17 months (95% CI: 14.7 – 19.3 months). The median OS of patients who attained PCR was 55 months (95% CI: 22.9 – 87.1 months) vs 16 months (95% CI: 13.9–18.1 months) for those who did not attain PCR (p=0.004). The corresponding 10-year OS were 21.1% (SE-3.2%) and 40.5% (SE-7.4%).
Conclusions
Pathological complete response is a surrogate marker of long-term overall survival in patients of technically unresectable oral cavity cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12